ArticleInterventional pain medicine2022
Lumbar medial branch block progression to radiofrequency neurotomy: A retrospective audit of clinical practice.
Article in Interventional pain medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic axial low back pain due to zygapophysial joint arthropathy is best diagnosed via lumbar medial branch block (MBB). However, the paradigm by which MBB is used to select patients for lumbar radiofrequency neurotomy (RFN) is contested. Dual diagnostic lumbar MBB with a minimum of ≥80% pain relief to diagnose lumbar zygapophysial joint pain are accepted by some Medicare Local Coverage Determination (LCD) as the method for selecting patients for RFN for the management of lumbar zygapophysial joint pain. However, some argue that dual diagnostic MBB and the ≥80% pain relief threshold lack utility in clinical practice, given that those that progress from MBB1 to MBB2 will then flow from MBB2 to RFN without fail. Study: Pragmatic retrospective clinical audit. Objective: Does clinical practice of dual diagnostic lumbar MBBs and an ≥80% pain improvement diagnostic threshold reduce patient eligibility for RFN after both MBB1 and MBB2? Results: Using dual diagnostic lumbar MBBs and an ≥80% pain improvement diagnostic threshold, 90/167 (54%, 95% CI 46-61%) patients successfully progressed from MBB1 to MBB2. Of those 90 patients, 66 patients (73%, 95% CI 64-82%) successfully progressed from MBB2 to RFN. Both MBB1 and MBB2 impacted the eligibility of the progression of 77/167 (46%, 95% CI 39-54%) patients and 24/90 patients (27%, 95% CI 18-36%), respectively. An additional sub-cohort analysis which included all the patients from the ≥80% pain relief cohort, and those who progressed at the discretion of the providers with 50-79% relief revealed that 124/167 patients (74%, 95% CI 68-81%) successfully progressed from MBB1 to MBB2. Of those 124 patients, 99 patients (80%, 95% CI 73-87%) progressed from MBB2 to RFN. In this laxer criteria cohort, MBB1 and MBB2 impacted the eligibility of the progression of 43/167 patients (26%, 95% CI 19-32%) and 25/124 patients (20%, 95% CI 13-27%), respectively. Conclusion: MBB1 and MBB2 both filtered patients from progression to lumbar RFN using dual MBBs with an ≥80% pain relief criteria. It also held true when using a more relaxed pain relief selection criterion as well. Dual MBB's and ≥80% pain improvement criteria as a selection paradigm led to half as many lumbar RFNs being performed when compared to a single MBB and ≥80% pain improvement criteria. In theory, a more rigid selection paradigm treats less patients but exposes fewer to unnecessary RFNs while a laxer selection paradigm treats more patients but exposes more to unnecessary RFNs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.